WuXi Vaccines has signed a partnership agreement, along with a 20-year vaccine manufacturing contract, valued approximately $3bn, with a global vaccine firm.

Under the terms of the agreement, WuXi Vaccines will construct a dedicated manufacturing facility and supply commercial vaccine products for the global market.

WuXi Vaccines chairman Chris Chen said: “This is a historic moment for WuXi Vaccines as well as for the global vaccine industry. Due to process complexity, extensive analytic testing and rigorous regulatory standards, vaccines are difficult to manufacture and process and quality control are extremely critical for the quality of the product.

“This partnership with a global vaccine leader to exclusively manufacture a vaccine for the global market, first of its kind in the industry, is a further testimony to the technical strengths and premier quality demonstrated by WuXi Vaccines, WuXi Vaccines will provide our global partners with a robust and premier-quality supply chain network to produce high-quality vaccines to protect human being globally.”

WuXi Vaccines will build an integrated manufacturing facility for vaccines

WuXi Vaccines is a joint venture vaccine Contract Development and Manufacturing Organization (CDMO) between WuXi Biologics and Shanghai Hile Bio-technology. The firm operates on a business model that builds advanced integrated platforms and CDMO model, for the development and manufacture of vaccines.

WuXi Biologics is a Hong Kong-based biologics technology provider that offers end-to-end solutions for discovery, development and manufacturing of biologics.

The JV firm will build an integrated manufacturing facility, equipped with drug substance manufacturing (DS), drug product manufacturing (DP), manufacture science and technology labs (MS&T) and quality control labs (QC) for vaccines.

The dedicated vaccine manufacture facility will produce vaccines developed by one of its industry partners and is expected to be operational in 2022.

In November 2019, the company has announced $240m investment in a new vaccine manufacturing facility, to be constructed within its campus, adjacent to its ‘Factory of the Future’ biologics drug substance manufacturing facility, in Ireland.